IP
RVNC

Intellectus Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Intellectus Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,000
Closed -$32K – 415
2019
Q1 		$32K Hold
2,000
– – 0.01% 281
2018
Q4 		$40K Hold
2,000
– – 0.03% 159
2018
Q3 		$50K Hold
2,000
– – 0.02% 348
2018
Q2 		$55K Hold
2,000
– – 0.02% 330
2018
Q1 		$62K Buy
+2,000
New +$64.3K 0.02% 316

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Intellectus Partners's RVNC Position: Q2 2019 in Review

Intellectus Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2019, closing a stake of 2,000 shares — an estimated $32K sold.

Intellectus Partners first reported a position in RVNC in Q1 2018 and held it in 5 quarters. The position peaked at $62K in Q1 2018. 114 funds tracked by Wall St. Rank hold RVNC as of Q2 2019.

  • Intellectus Partners reported no remaining Revance Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Intellectus Partners sold 2,000 Revance Therapeutics, Inc. shares in Q2 2019, an estimated $32K.
  • Intellectus Partners first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
  • Intellectus Partners's Revance Therapeutics, Inc. position peaked at $62K in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2019.

Based on Intellectus Partners's 13F filing for Q2 2019, filed 8 Aug 2019.